Who makes Tucatinib 150 MG?

Tucatinib 150 MG is developed by Pfizer Inc..

What development phase is Tucatinib 150 MG in?

Tucatinib 150 MG is in Phase 2.

What is the generic name of Tucatinib 150 MG?

tucatinib-150-mg is the generic (nonproprietary) name of Tucatinib 150 MG.

Last reviewed 2026-04-20 · How we verify

Tucatinib 150 MG (tucatinib-150-mg)

Pfizer Inc. · Phase 2 active Small molecule Quality 0/100

At a glance

Generic name	tucatinib-150-mg
Sponsor	Pfizer Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) (PHASE1)
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tucatinib 150 MG CI brief — competitive landscape report
Tucatinib 150 MG updates RSS · CI watch RSS
Pfizer Inc. portfolio CI